Turn Therapeutics

What Turn Therapeutics does

Turn Therapeutics is a clinical-stage biotechnology company developing first-in-class topical cytokine-modulating therapeutics and FDA-cleared medical devices for dermatology, wound care, and infectious disease. The company is built on its proprietary PermaFusion® drug delivery platform, an oil-based formulation technology that enables water-soluble therapeutic agents to penetrate deeper tissue layers without emulsifiers or adjuvants, allowing topical delivery of molecules that would normally require injection. The lead clinical asset is GX-03, a non-systemic therapy targeting IL-36α, IL-36γ, IL-31, and IL-4 for moderate-to-severe atopic dermatitis; Phase 2 interim data showed 92.6% of treated subjects achieving EASI-50 within 4 weeks and 70.4% achieving EASI-75, with no treatment-related serious adverse events. The company also markets three FDA 510(k)-cleared medical devices (Hexagen Wound Dressing, XEAL, and FLEX AM) that have collectively recorded over 200,000 human uses with zero reported adverse events.

Name

Turn Therapeutics

Legal name

Global Health Solutions, Inc.

Website

https://turntherapeutics.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Turn Therapeutics is a clinical-stage biotechnology company developing first-in-class topical cytokine-modulating therapies (lead candidate GX-03 for atopic dermatitis) and FDA-cleared wound care devices, all powered by its proprietary PermaFusion® drug delivery platform.

Ownership category

akta.pro rank

Product category

Dermatology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medical Equipment and Supplies Manufacturing (3391)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Dermatology Specialty Pharmaceuticals (HLAIACAL), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

Keywords

• Topical cytokine modulators
• Inflammatory skin disease therapies
• Drug delivery platform
• Antimicrobial wound dressings
• Clinical-stage biotechnology

Headquarters

HQ city

Calabasas

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Medical Device Sales & Licensing: Revenue generated through global supply, development, and license agreement with Medline for commercialization of products using PermaFusion platform. FDA-cleared medical devices including Hexagen Wound Dressing and XEAL Antimicrobial Oil Emulsion Dressing generate revenue through licensing and supply arrangements. MIMEDX partnership for FLEX AM includes $70M+ milestone potential.
2. Future Drug Product Sales: Upon regulatory approval, GX-03 for atopic dermatitis and onychomycosis will be commercialized through traditional retail pharmacy channels. Moderate-to-severe eczema market growing at 15% CAGR, forecast to reach nearly $30B by 2031.
3. Crowdfunding and Public Market Capital: Company conducted Regulation Crowdfunding campaigns through StartEngine enabling retail investor participation. Direct listing on Nasdaq (TTRX) in October 2025 provides ongoing capital market access.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Turn Therapeutics develops first-in-class topical cytokine-modulating therapeutics powered by its proprietary PermaFusion® oil-based drug delivery platform for inflammatory skin diseases, with lead candidate GX-03 in Phase 2 trials for moderate-to-severe atopic dermatitis. The company also markets FDA-cleared antimicrobial medical devices (Hexagen Wound Dressing, XEAL, FLEX AM, AtopX) for wound care and dermatology through enterprise licensing partners Medline and MIMEDX. Commercial revenue is generated via licensing and supply arrangements, with future drug sales planned through retail pharmacy channels upon regulatory approval.

Product overview

Turn Therapeutics is a clinical-stage biotechnology company developing a portfolio of first-in-class topical therapeutics powered by its proprietary PermaFusion® drug delivery platform. The core product is GX-03, a non-systemic cytokine-modulating therapy targeting IL-36 and IL-31 for inflammatory skin diseases. The company also markets FDA-cleared medical devices including Hexagen Wound Dressing, XEAL, FLEX AM, and AtopX. An intranasal vaccine candidate is in development leveraging the same PermaFusion technology for enhanced stability.

Differentiator

Problem solved

Functional benefit

Brands

• PermaFusion: Proprietary drug delivery platform that enables water-soluble therapeutic agents to penetrate deeper tissue layers without emulsifiers, adjuvants, or unnecessary additives.
• Hexagen
• XEAL
• FLEX AM
• AtopX

Products and services

• GX-03 First-in-class non-systemic topical cytokine-modulating therapy targeting IL-36α, IL-36γ, IL-31, and IL-4 for moderate-to-severe atopic dermatitis and onychomycosis. Currently in Phase 2 clinical trials with interim data showing 92.6% EASI-50 and 70.4% EASI-75 within 4 weeks.
• PermaFusion® Platform Proprietary oil-based drug delivery platform enabling water-soluble therapeutic agents to penetrate deeper tissue layers without emulsifiers or adjuvants. Underpins Turn's therapeutic pipeline and FDA-cleared medical devices, protected by 15+ patents.
• Hexagen Wound Dressing FDA-cleared antimicrobial oil emulsion wound dressing with petrolatum-based formulation. Has over 200,000 human uses with zero reported adverse events. Commercialized globally through Medline partnership.
• XEAL Antimicrobial Oil Emulsion Dressing

Quantifiable outcome

• 92.6% of GX-03-treated subjects achieved at least 50% reduction in eczema severity within 4 weeks (EASI-50)
• +5 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered flagship, strategic and major.

• MedlineflagshipStrategic or Co-development Partner · 30 October 2025Global supply, development, and license agreement with Medline (largest provider of medical-surgical products) to develop, manufacture, and commercialize products using Turn's PermaFusion platform. Medline employs 43,000+ people and operates in over 100 countries. Expected to generate revenue beginning late 2026 in advanced wound care market.
• International AIDS Vaccine Initiative (IAVI)strategicStrategic or Co-development Partner · 2 May 2025Partnership to develop thermostable intranasal vaccine using IAVI's rVSV-MARV vector in Turn's proprietary oil-based delivery system. Validated 100% recovery of VSV after 24 and 72 hours in oil carrier at room temperature. Collaboration advancing multi-arm stability studies.
• MIMEDXmajorChannel Partner/ Reseller/ DistributorExclusive licensing of FLEX AM (Antimicrobial Collagen Powder) to MIMEDX for wound care applications. Partnership includes $70M+ milestone potential. MIMEDX focuses on regenerative medicine.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Arcutis Biotherapeutics: Direct competitor developing topical therapeutics for inflammatory skin diseases including atopic dermatitis (ZORYVE cream); both companies pursue topical alternatives to systemic biologics in the same dermatology space with similar regulatory and commercial pathways.
• Dermavant Sciences: Develops topical therapeutics for inflammatory skin diseases (VTAMA/tapinarof cream for psoriasis and atopic dermatitis); competes head-to-head with Turn's GX-03 in the topical non-steroidal dermatology category.
• Incyte Corporation: Markets Opzelura (ruxolitinib cream), a topical JAK inhibitor approved for atopic dermatitis; directly competes with GX-03 in the topical inflammatory skin disease market with established commercial infrastructure.
• MiMedx Group: Exclusive licensee of Turn's FLEX AM antimicrobial collagen powder and a peer in regenerative wound care; comparable business model focused on biologics for advanced wound management with similar distribution channels.
• Organogenesis Holdings: Commercial-stage regenerative medicine company selling wound care biologics (Apligraf, Dermagraft) into the same advanced wound care market where Turn's Hexagen, XEAL, and FLEX AM compete; closely comparable product portfolio and customer base.

Broad incumbents

• Regeneron Pharmaceuticals: Co-develops and commercializes Dupixent (dupilumab) with Sanofi, the dominant systemic biologic for moderate-to-severe atopic dermatitis; defines the standard-of-care that Turn's topical approach aims to differentiate from.
• AbbVie: Markets Rinvoq (upadacitinib), an oral JAK inhibitor approved for atopic dermatitis; broader immunology incumbent competing for the same moderate-to-severe patient population Turn targets.
• Galderma: Dermatology-focused pharmaceutical company developing nemolizumab (IL-31 inhibitor biologic) and other inflammatory skin disease therapeutics; overlaps with Turn's cytokine-targeting approach and shares the dermatology specialty channel.

Others

• Medline Industries: Largest privately-held manufacturer and distributor of medical-surgical products and Turn's global commercialization partner for PermaFusion-based products; relevant as channel partner and scale benchmark in advanced wound care.

Emerging players

• Castle Biosciences: Emerging dermatology-focused commercial-stage company with skin-inflammation and diagnostics pipeline; comparable in size and stage profile to Turn, also pursuing dermatology specialty markets with proprietary technologies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/hexagenhealing

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Turn Therapeutics